drugset / Trial / NCT04764513
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
This study investigates the infusion safety and potential curative properties of ex-vivo expanded γδ T cells obtained from the same donor for patients who have hematological malignancies and have accepted allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2021-09-12
- Primary completion
- 2023-04
- Completion
- 2025-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ex-vivo expanded γδ T cell | Cell therapy | 2e+06 cells/kg | — |
| Subject | Ex-vivo expanded γδ T cell | Cell therapy | 1e+07 cells/kg | — |
| Subject | Ex-vivo expanded γδ T cell | Cell therapy | 5e+07 cells/kg | — |